Monoclonal and bispecific antibodies as novel therapeutics

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 2, 2006, Pages 85-101

  Booy, Evan P ^a,b   Johar, Dina ^a,b   Maddika, Srilekha ^a,b   Pirzada, Hasan ^a   Sahib, Mickey M ^b   Gehrke, Iris ^a   Loewen, Shauna ^a,b   Louis, Sherif F ^a   Kadkhoda, Kamran ^a,b   Mowat, Michael ^a,b   Los, Marek ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bexxar; Gleevec; Imantib; Mitumomab; Tositumomab; Trastuzumab

Indexed keywords

[4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ALEMTUZUMAB; AZD 0530; BEC 2; BEVACIZUMAB; BISPECIFIC ANTIBODY; BOSUTINIB; CEA VAC; CETUXIMAB; CG 76030; DACLIZUMAB; DASATINIB; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; IMATINIB; MASTUZUMAB; MATUZUMAB; MDX 210; MITUMOMAB; MONOCLONAL ANTIBODY; OREGOVOMAB; PANITUMUMAB; PEMTUMOMAB; PHOSPHOTRANSFERASE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRIAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER; CARDIOTOXICITY; CELL SURVIVAL; CHILL; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; FEVER; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYBRIDIZATION; HYPERTENSION; IMMUNOPATHOLOGY; MUCOSA INFLAMMATION; NONHUMAN; ONCOGENE; PROGNOSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; TUMOR GROWTH;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 33747465510     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0011-5     Document Type: Review

References (167)

1. Abicht A. and Lochmuller H. (2000): Technology evaluation: edrecolomab, Centocor Inc. Curr. Opin. Mol. Ther., 2, 593-600.
2. Akiyama T., Sudo C., Ogawara H., Toyoshima K.and Yamamoto T. (1986): The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-1646.
3. Bander N. H., Trabulsi E. J., Kostakoglu L., Yao D., Vallabhajosula S., Smith-Jones P., Joyce M. A., Milowsky M., Nanus D. M. and Goldsmith S. J. (2003): Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol., 170, 1717-1721.
4. Barczyk K., Kreuter M., Pryjma J., Booy E. P., Maddika S., Ghavami S., Berdel W. E., Roth J. and Los M. (2005): Serum cytochrome c indicates in vivo-apoptosis and can serve as a prognostic marker during cancer therapy. Int. J. Cancer, 114, 167-173.
5. Ben-Ari Z., Schmilovotz-Weiss H., Belinki A., Pappo O., Sulkes J., Neuman M. G., Kaganovsky E., Kfir B., Tur-Kaspa R. and Klein T. (2003): Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J. Intern. Med., 254, 168-175.
6. Blagosklonny M. V. and Darzynkiewicz Z. (2005): Strategies of protection of normal cells during chemo- and radio-therapy based on modulation of cell cycle and apoptotic pathways. In: Los M. and Gibson S. B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases. Springer Science+Business Media, Inc., New York, 357-391.
7. Blaschuk O. W. and Rowlands T. M. (2002): Plasma membrane components of adherens junctions. Mol. Membr. Biol., 19, 75-80.
8. Booy E. P., Kadkhoda K., Johar D., Bay G. H. and Los M. (2005): The immune system, involvement in neurodegenerative diseases, ageing and cancer. Curr. Med. Chem. Anti-Inflammatory Anti-Allergy Agents, 4, 349-353.
9. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K. P. and Hughes T. P. (2002): High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99, 3472-3475.
10. Bross P. F., Beitz J., Chen G., Chen X. H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G. and Pazdur R. (2001): Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res., 7, 1490-1496.
11. Brown J. G. and Gibson S. B. (2005): Growth factors, receptors, and kinases: their exploration to target cancer. In: Los M. and Gibson S. B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases: Springer Science + Business Media, Inc., New York, 173-196.
12. Bruggemann M., Williams G. T., Bindon C. I., Clark M. R., Walker M. R., Jefferis R., Waldmann H. and Neuberger M. S. (1987): Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med., 166, 1351-1361.
13. Bruggemann M., Winter G., Waldmann H. and Neuberger M. S. (1989): The immunogenicity of chimeric antibodies. J. Exp. Med., 170, 2153-2157.
14. Brunton V. G., Avizienyte E., Fincham V. J., Serrels B., Metcalf C. A. 3rd, Sawyer T. K. and Frame M. C. (2005): Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res., 65, 1335-1342.
15. Bullani R. R., Wehrli P., Viard-Leveugle I., Rimoldi D., Cerottini J. C., Saurat J. H., Tschopp J. and French L. E. (2002): Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res., 12, 263-270.
16. Bunn P. A. Jr. and Franklin W. (2002): Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol., 29, 38-44.
17. Burtness B. A., Li Y., Flood W., Mattar B. I. and Forastiere A. (2003): Phase III randomized trial of cisplatin plus placebo versus cisplatin+C225, a monoclonal antibody directed to the epidermal growth factor-receptor: An Eastern Cooperative Oncology Group trial. Clin. Cancer Res., 9, 6088S.
18. Canevari S., Mezzanzanica D., Mazzoni A., Negri D. R., Ramakrishna V., Bolhuis R. L., Colnaghi M. I. and Bolis G. (1995): Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J. Hematother., 4, 423-427.
19. Caponigro F., Formato R., Caraglia M., Normanno N. and Iaffaioli R. V. (2005): Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr. Opin. Oncol., 17, 212-217.
20. Carter P. (2001): Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 1, 118-129.
21. Carter P., Presta L., Gorman C. M., Ridgway J. B., Henner D., Wong W. L., Rowland A. M., Kotts C., Carver M. E. and Shepard H. M. (1992): Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89, 4285-4289.
22. Cassens U., Lewinski G., Samraj A. K., von Bernuth H., Baust H., Khazaie K. and Los M. (2003): Viral modulation of cell death by inhibition of caspases. Arch. Immunol. Ther. Exp., 51, 19-27.
23. Chinn P. C., Leonard J. E., Rosenberg J., Hanna N. and Anderson D. R. (1999): Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol., 15, 1017-1025.
24. Chlichlia K., Schirrmacher V. and Sandaltzopoulos R. (2005): Cancer immunotherapy: Battling tumors with gene vaccines. Curr. Med. Chem. Anti-Inflammatory Anti-Allergy Agents, 4, 353-366.
25. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., Fan Z., Mendelsohn J., Bianco A. R. and Tortora G. (1999): Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5, 909-916.
26. Clynes R. A., Towers T. L., Presta L. G. and Ravetch J. V. (2000): Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 6, 443-446.
27. Coleman M., Goldenberg D. M., Siegel A. B., Ketas J. C., Ashe M., Fiore J. M. and Leonard J. P. (2003): Epratuzumab: targeting B-cell malignancies through CD22. Clin. Cancer Res., 9, 3991S-3994S.
28. Corbin A. S., Demehri S., Griswold I. J., Wang Y., Metcalf Iii C. A., Sundaramoorthi R., Shakespeare W. C., Snodgrass J., Wardwell S., Dalgarno D., Iuliucci J., Sawyer T., Heinrich M. C., Druker B. J. and Deininger M. W. (2005): In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation loop mutants of kit. Blood, 106, 227-234.
29. Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. et al. (1985): Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139.
30. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I. and Van Cutsem E. (2004): Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 351, 337-345.
31. Deininger M. W., O'Brien S. G., Ford J. M. and Druker B. J. (2003): Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol., 21, 1637-1647.
32. Dhein J., Walczak H., Baumler C., Debatin K. M. and Krammer P. H. (1995): Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373, 438-441.
33. Druker B. J. (2003): Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol., 40, 50-58.
34. Druker B. J. and Lydon N. B. (2000): Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest., 105, 3-7.
35. Druker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M., Lydon N. B., Kantarjian H., Capdeville R., Ohno-Jones S. and Sawyers C. L. (2001): Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344, 1031-1037.
36. Dumont F. J. (2002): CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev. Anticancer Ther., 2, 23-35.
37. Fialkow P. J., Jacobson R. J. and Papayannopoulou T. (1977): Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med., 63, 125-130.
38. Flossmann-Kast B. B., Jehle P. M., Hoeflich A., Adler G. and Lutz M. P. (1998): Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res., 58, 3551-3554.
39. Foon K. A., John W. J., Chakraborty M., Das R., Teitelbaum A., Garrison J., Kashala O., Chatterjee S. K. and Bhattacharya-Chatterjee M. (1999): Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol., 17, 2889-2885.
40. Freeman S. D., Kelm S., Barber E. K. and Crocker P. R. (1995): Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85, 2005-2012.
41. Gambacorti-Passerini C. B., Gunby R. H., Piazza R., Galietta A., Rostagno R. and Scapozza L. (2003): Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol., 4, 75-85.
42. Gatto B. (2004): Monoclonal antibodies in cancer therapy. Curr. Med. Chem. Anti-Cane. Agents, 4, 411-414.
43. Ghavami S., Hashemi M., Kadkhoda K., Alavian S. M., Bay G. H. and Los M. (2005): Apoptosis in liver diseases - detection and therapeutic applications. Med. Sci. Monit., 11, RA337-345.
44. Ghavami S., Kerkhoff C., Los M., Hashemi M., Sorg C. and Karami-Tehrani F. (2004): Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J. Leukoc. Biol., 76, 169-175.
45. Ghetie V. and Ward E. S. (2000): Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol., 18, 739-766.
46. Giles F., Estey E. and O'Brien S. (2003): Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer, 98, 2095-2104.
47. Glennie M. J. and Johnson P. W. (2000): Clinical trials of antibody therapy. Immunol. Today, 21, 403-410.
48. Golas J. M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., Frost P., Ye F., Boschelli D. H. and Boschelli F. (2003): SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 63, 375-381.
49. Grillo-Lopez A. J. (2000): Rituximab: an insider's historical perspective. Semin. Oncol., 27, 9-16.
50. Grillo-Lopez A. J., White C. A., Dallaire B. K., Varns C. L., Shen C. D., Wei A., Leonard J. E., McClure A., Weaver R., Cairelli S. and Rosenberg J. (2000): Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol., 1, 1-9.
51. Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R. and Grosveld G. (1984): Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36, 93-99.
52. Gupta R. A. and Dubois R. N. (2001): Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 1, 11-21.
53. Hale G. and Waldmann H. (1996): Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant., 17, 305-308.
54. Haller D. G. (2001): Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer. Semin. Oncol., 28, 25-30.
55. Hamann P. R., Hinman L. M., Beyer C. F., Lindh D., Upeslacis J., Shochat D. and Mountain A. (2005): A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug. Chem., 16, 354-360.
56. Hamby J. M., Connolly C. J., Schroeder M. C., Winters R. T., Showalter H. D., Panek R. L., Major T. C., Olsewski B., Ryan M. J., Dahring T., Lu G. H., Keiser J., Amar A., Shen C., Kraker A. J., Slintak V., Nelson J. M., Fry D. W., Bradford L., Hallak H. and Doherty A. M. (1997): Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem., 40, 2296-2303.
57. Hashemi M., Karami-Tehrani F., Ghavami S., Maddika S. and Los M. (2005): Adenosine and deoxyadenosine induces apoptosis in estrogen receptor positive and negative human breast cancer cells via the intrinsic pathway. Cell Prolif., 38, 269-285.
58. Hauff K., Zamzow C., Law W. J., de Melo J., Kennedy K. and Los M. (2005): Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. Arch. Immunol. Ther. Exp., 53, 308-320.
59. Heisterkamp N., Stephenson J. R., Groffen J., Hansen P. F., de Klein A., Bartram C. R. and Grosveld G. (1983): Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306, 239-242.
60. Heldin C. H. (1995): Dimerization of cell surface receptors in signal transduction. Cell, 80, 213-223.
61. Herbst R. S. and Shin D. M. (2002): Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer, 94, 1593-1611.
62. Hochhaus A., Kreil S., Corbin A. S., La Rosee P., Muller M. C., Lahaye T., Hanfstein B., Schoch C., Cross N. C., Berger U., Gschaidmeier H., Druker B. J. and Hehlmann R. (2002): Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16, 2190-2196.
63. Holliger P., Wing M., Pound J. D., Bohlen H. and Winter G. (1997): Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol., 15, 632-636.
64. Hong F., Hansen R. D., Yan J., Allendorf D. J., Baran J. T., Ostroff G. R. and Ross G. D. (2003): Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res., 63, 9023-9031.
65. Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., Hallek M., Van Etten R. A. and Li S. (2004): Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet., 36, 453-461.
66. Huang S., Armstrong E. A., Benavente S., Chinnaiyan P. and Harari P. M. (2004): Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res., 64, 5355-5362.
67. Huron D. R., Gorre M. E., Kraker A. J., Sawyers C. L., Rosen N. and Moasser M. M. (2003): A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res., 9, 1267-1273.
68. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R. and Kabbinavar F. (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350, 2335-2342.
69. Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W. F. and Kabbinavar F. (2005): Bevacizumab in combination with Fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin.Oncol., 23, 3502-3508.
70. Indar A., Maxwell-Armstrong C. A., Durrant L. G., Carmichael J. and Scholefield J. H. (2002): Current concepts in immunotherapy for the treatment of colorectal cancer. J. R. Coll. Surg. Edinb., 47, 458-474.
71. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y. and Nagata S. (1991): The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-243.
72. Janssen R. A., Kroesen B. J., Buter J., Mesander G., Sleijfer D. T., The T. H., Mulder N. H. and de Leij L. (1995): Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. Br. J. Cancer, 72, 795-799.
73. Jedema I., Barge R. M., van der Velden V. H., Nijmeijer B. A., van Dongen J. J., Willemze R. and Falkenburg J. H. (2004): Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 18, 316-325.
74. Johar D., Roth J. C., Bay G. H., Walker J. N., Kroczak T. J. and Los M. (2004): Inflammatory response, reactive oxygen species, programmed (necrotic-like and apoptotic) cell death and cancer. Rocz. Akad. Med. Bialymst., 49, 31-39.
75. Jung G., Brandl M., Eisner W., Fraunberger P., Reifenberger G., Schlegel U., Wiestler O. D., Reulen H. J. and Wilmanns W. (2001): Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. J. Cancer, 91, 225-230.
76. Jung G., Grosse-Hovest L., Krammer P. H. and Rammensee H. G. (2001): Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res., 61, 1846-1848.
77. Kabore A. F., Johnston J. B. and Gibson S. B. (2004): Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr. Cancer Drug Targets, 4, 147-163.
78. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S. G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M. and Morra E. (2002): Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346, 645-652.
79. Kerkhoff C. and Ghavami S. (2005): Induction of apoptotic cell death in tumor cells by s100a8/a9 released from inflammatory cells upon cellular activation. Curr. Med. Chem.-Anti-Inflammatory Anti-Allergy Agents, 4, 383-392.
80. Kitada S., Andersen J., Akar S., Zapata J. M., Takayama S., Krajewski S., Wang H. G., Zhang X., Bullrich F., Croce C. M., Rai K., Hines J. and Reed J. C. (1998): Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood, 91, 3379-3389.
81. Kolibaba K. S. and Druker B. J. (1997): Protein tyrosine kinases and cancer. Biochim. Biophys. Acta, 1333, F217-248.
82. Kortt A. A., Dolezal O., Power B. E. and Hudson P. J. (2001): Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng., 18, 95-108.
83. Kreuter M., Langer C., Kerkhoff C., Reddanna P., Kania A. L., Maddika S., Chlichlia K., Bui T. N. and Los M. (2004): Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch. Immunol. Ther. Exp., 52, 141-155.
84. Lewington V. (2005): Development of 131I-tositumomab. Semin. Oncol., 32, S50-6.
85. Lewis G. D., Figari I., Fendly B., Wong W. L., Carter P., Gorman C. and Shepard H. M. (1993): Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37, 255-263.
86. Li R., Xiong D. S., Shao X. F., Liu J., Xu Y. F., Xu Y. S., Liu H. Z., Zhu Z. P. and Yang C. Z. (2004): Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II. Acta Pharmacol. Sin., 25, 1292-1298.
87. Li Y., Tian Z., Rizvi S. M., Bander N. H. and Allen B. J. (2002): In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis., 5, 36-46.
88. Loeffler M. and Kroemer G. (2000): The mitochondrion in cell death control: certainties and incognita. Exp. Cell Res., 256, 19-26.
89. Los M., Burek C. J., Stroh C., Benedyk K., Hug H. and Mackiewicz A. (2003): Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today, 8, 67-77.
90. Los M., Khazaie K., Schulze Osthoff K., Baeuerle P. A., Schirrmacher V. and Chlichlia K. (1998): Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. J. Immunol., 161, 3050-3055.
91. Los M., van de Craen M., Penning C. L., Schenk H., Westendorp M., Baeuerle P. A., Dröge W., Krammer P. H., Fiers W. and Schulze-Osthoff K. (1995): Requirement of an ICE/Ced-3 protease for Fas/Apo-1-1mediated apoptosis. Nature, 371, 81-83.
92. Los M., Wesselborg S. and Schulze Osthoff K. (1999): The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity, 10, 629-639.
93. Lutz M. P., Esser I. B., Flossmann-Kast B. B., Vogelmann R., Luhrs H., Friess H., Buchler M. W. and Adler G. (1998): Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun., 243, 503-508.
94. Maddika S., Booy E. P., Johar D., Gibson S. B., Ghavami S. and Los M. (2005): Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell death mediators by a Nur77-dependent pathway. J. Cell Sci., 118, 4485-4493.
95. Mann M., Sheng H., Shao J., Williams C. S., Pisacane P. I., Sliwkowski M. X. and DuBois R. N. (2001): Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 120, 1713-1719.
96. Manzke O., Titzer S., Tesch H., Diehl V. and Bohlen H. (1997): CD3xCD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Cancer Immunol. Immunother., 45, 198-202.
97. Marks A. J., Cooper M. S., Anderson R. J., Orchard K. H., Hale G., North J. M., Ganeshaguru K., Steele A. J., Mehta A. B., Lowdell M. W. and Wickremasinghe R. G. (2005): Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res., 65, 2373-2377.
98. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., Guzman M., Rodriguez S., Arribas J., Palacios J. and Baselga J. (2004): Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over singleagent receptor targeting. Clin. Cancer Res., 10, 6487-6501.
99. Mauer A. M., Cohen E. E. W., Wong S. J., Kozloff M., Winegarden J., Gustin D. M. and Vokes E. E. (2004): Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol., 23, 497S-497S.
100. Mendoza F. J., Espino P. S., Cann K. L., Bristow N., McCrea K. and Los M. (2005): Anti-tumor chemotherapy utilizing peptide-based approaches-apoptotic pathways, kinases, and proteasome as targets. Arch. Immunol. Ther. Exp., 53, 47-60.
101. Milowsky M. I., Nanus D. M., Kostakoglu L., Vallabhajosula S., Goldsmith S. J. and Bander N. H. (2004): Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol., 22, 2522-2531.
102. Mitrus I., Missol-Kolka E., Plucienniczak A. and Szala S. (2005): Tumour therapy with genes encoding apoptin and E4orf4. Anticancer Res., 25, 1087-1090.
103. Modjtahedi H. and Dean C. (1995): The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists. Biochem. Biophys. Res. Commun., 207, 389-397.
104. Molema G., Tervaert J. W., Kroesen B. J., Helfrich W., Meijer D. K. and de Leij L. F. (2000): CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro. Br. J. Cancer, 82, 472-479.
105. Nagar B., Bornmann W. G., Pellicena P., Schindler T., Veach D. R., Miller W. T., Clarkson B. AND Kuriyan J. (2002): Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 62, 4236-4243.
106. Nahta R., Hortobagyi G. N. and Esteva F. J. (2003): Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist, 8, 5-17.
107. Nanus D. M., Milowsky M. I., Kostakoglu L., Smith-Jones P. M., Vallabahajosula S., Goldsmith S. J. and Bander N. H. (2003): Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol., 170, S84-88; discussion S88-89.
108. Naundorf S., Preithner S., Mayer P., Lippold S., Wolf A., Hanakam F., Fichtner I., Kufer P., Raum T., Riethmuller G., Baeuerle P. A. and Dreier T. (2002): In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int. J. Cancer, 100, 101-110.
109. Neet K. and Hunter T. (1995): The nonreceptor protein-tyrosine kinase CSK complexes directly with the GTPase-activating protein-associated p62 protein in cells expressing v-Src or activated c-Src. Mol. Cell Biol., 15, 4908-4920.
110. Nitta T., Sato K., Yagita H., Okumura K. and Ishii S. (1990): Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335, 368-371.
111. O'Brien S. G., Guilhot F., Larson R. A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J. J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J. L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J. M., Kantarjian H., Taylor K., Verhoef G., Bolton A. E., Capdeville R. and Druker B. J. (2003): Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 348, 994-1004.
112. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T. and Nagata S. (1993): Lethal effect of the anti-Fas antibody in mice. Nature, 364, 806-809.
113. Pangalis G. A., Dimopoulou M. N., Angelopoulou M. K., Tsekouras C., Vassilakopoulos T. P., Vaiopoulos G. and Siakantaris M. P. (2001): Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disor-ders. Med. Oncol., 18, 99-107.
114. Panigrahi S. and Mai S. (2005): Telomeres, genomic instability, DNA repair and Breast Cancer. Curr. Med. Chem. Anti-Inflammatory Anti-Allergy Agents, 4, 421-428.
115. Park J. W., Hong K., Kirpotin D. B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U. B., Marks J. D., Moore D., Papahadjopoulos D. and Benz C. C. (2002): Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 8, 1172-1181.
116. Passos-Bueno M. R., Wilcox W. R., Jabs E. W., Sertie A. L., Alonso L. G. and Kitoh H. (1999): Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat., 14, 115-125.
117. Peiper S. C., Ashmun R. A. and Look A. T. (1988): Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood, 72, 314-321.
118. Pezzutto A., Dorken B., Rabinovitch P. S., Ledbetter J. A., Moldenhauer G. and Clark E. A. (1987): CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J. Immunol., 138, 2793-2799.
119. Philchenkov A., Zavelevich M., Kroczak T. J. and Los M. (2004): Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol., 26, 82-97.
120. Raff M. C. (1992): Social controls on cell survival and cell death. Nature, 356, 397-400.
121. Renz A., Berdel W. E., Kreuter M., Belka C., Schulze-Osthoff K. and Los M. (2001): Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood, 98, 1542-1548.
122. Robinson M. K., Weiner L. M. and Adams G. P. (2004): Improving monoclonal antibodies for cancer therapy. Drug Dev. Res., 61, 172-187.
123. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J. L., Philippe N., Facon T., Fenaux P. and Preudhomme C. (2002): Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100, 1014-1018.
124. Rooseboom M., Commandeur J. N. and Vermeulen N. P. (2004): Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev., 56, 53-102.
125. Ross J. S., Gray K., Gray G. S., Worland P. J. and Rolfe M. (2003): Anticancer antibodies. Am. J. Clin. Pathol., 119, 472-485.
126. Roumiantsev S., Shah N. P., Gorre M. E., Nicoll J., Brasher B. B., Sawyers C. L. and Van Etten R. A. (2002): Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA, 99, 10700-10705.
127. Rowinsky E. K., Schwartz G. H., Gollob J. A., Thompson J. A., Vogelzang N. J., Figlin R., Bukowski R., Haas N., Lockbaum P., Li Y. P., Arends R., Foon K. A., Schwab G. and Dutcher J. (2004): Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol., 22, 3003-3015.
128. Rowley J. D. (1973): Chromosomal patterns in myelocytic leukemia. N. Engl. J. Med., 289, 220-221.
129. Rowley J. D. (1973): Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
130. Sadowski-Debbing K., Coy J. F., Mier W., Hug H. and Los M. (2002): Caspases - their role in apoptosis and other physiological processes as revealed by knock-out studies. Arch. Immunol. Ther. Exp., 50, 19-34.
131. Samel D., Muller D., Gerspach J., Assohou-Luty C., Sass G., Tiegs G., Pfizenmaier K. and Wajant H. (2003): Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J. Biol. Chem., 278, 32077-32082.
132. Sawyer T. K. (2004): Novel oncogenic protein kinase inhibitors for cancer therapy. Curr. Med. Chem. Anti-Canc. Agents, 4, 449-455.
133. Sawyer T. K., Bohacek R. S., Metcalf C. A. 3rd, Shakespeare W. C., Wang Y., Sundaramoorthi R., Keenan T., Narula S., Weigele M. and Dalgarno D. C. (2003): Novel protein kinase inhibitors: SMART drug design technology. Biotechniques, Suppl. 2-10, 12-15.
134. Sawyers C. L., Hochhaus A., Feldman E., Goldman J. M., Miller C. B., Ottmann O. G., Schiffer C. A., Talpaz M., Guilhot F., Deininger M. W., Fischer T., O'Brien S. G., Stone R. M., Gambacorti-Passerini C. B., Russell N. H., Reiffers J. J., Shea T. C., Chapuis B., Coutre S., Tura S., Morra E., Larson R. A., Saven A., Peschel C., Gratwohl A., Mandelli F., Ben-Am M., Gathmann I., Capdeville R., Paquette R. L. and Druker B. J. (2002): Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99, 3530-3539.
135. Schenk P. W. and Snaar-Jagalska B. E. (1999): Signal perception and transduction: the role of protein kinases. Biochim. Biophys. Acta, 1449, 1-24.
136. Schlessinger J. (2000): New roles for Src kinases in control of cell survival and angiogenesis. Cell, 100, 293-296.
137. Schwartzberg L. S. (2001): Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol., 40, 17-24.
138. Segal D. M., Weiner G. J. and Weiner L. M. (1999): Bispecific antibodies in cancer therapy. Curr. Opin. Immunol., 11, 558-562.
139. Shah N. P., Tran C., Lee F. Y., Chen P., Norris D. and Sawyers C. L. (2004): Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, 399-401.
140. Shan D., Ledbetter J. A. and Press O. W. (1998): Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 91, 1644-1652.
141. Shinbori T., Walczak H. and Krammer P. H. (2004): Activated T killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-alpha. Eur. J. Immunol., 34, 1762-1770.
142. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A. and McGuire W. L. (1987): Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
143. Stern D. F., Heffernan P. A. and Weinberg R. A. (1986): p185, a product of the neu proto-oncogene, is a receptor -like protein associated with tyrosine kinase activity. Mol. Cell Biol., 6, 1729-1740.
144. Stern M. and Herrmann R. (2005): Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol., 54, 11-29.
145. Stupack D. G. and Cheresh D. A. (2002): Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci., 115, 3729-3738.
146. Surmacz E. (2003): Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene, 22, 6589-6597.
147. Taetle R., Dos Santos B., Ohsugi Y., Koishihara Y., Yamada Y., Messner H. and Dalton W. (1994): Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. J. Natl. Cancer Inst., 86, 450-455.
148. Talpaz M., Silver R. T., Druker B. J., Goldman J. M., Gambacorti-Passerini C., Guilhot F., Schiffer C. A., Fischer T., Deininger M. W., Lennard A. L., Hochhaus A., Ottmann O. G., Gratwohl A., Baccarani M., Stone R., Tura S., Mahon F. X., Fernandes-Reese S., Gathmann I., Capdeville R., Kantarjian H. M. and Sawyers C. L. (2002): Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99, 1928-1937.
149. Taylor S. S., Radzio-Andzelm E. and Hunter T. (1995): How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. FASEB J., 9, 1255-1266.
150. Tibben J. G., Boerman O. C., Massuger L. F., Schijf C. P., Claessens R. A. and Corstens F. H. (1996): Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int. J. Cancer, 66, 477-483.
151. Toyoshima K., Semba K., Akiyama T., Ikawa S. and Yamamoto T. (1986): The c-erbB-2 gene encodes a receptor-like protein with tyrosine kinase activity. Cold Spring Harb. Symp. Quant. Biol., 51 (Pt 2), 977-982.
152. Trauth B. C., Klas C., Peters A. M., Matzku S., Moller P., Falk W., Debatin K. M. and Krammer P. H. (1989): Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245, 301-305.
153. Vallera D. A., Elson M., Brechbiel M. W., Dusenbery K. E., Burns L. J., Jaszcz W. B., Ramsay N. K., Panoskaltsis-Mortar A., Kuroki D. W., Wagner J. E., Vitetta E. S. and Kersey J. H. (2004): Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother. Radiopharm., 19, 11-23.
154. von Mehren M., Adams G. P. and Weiner L. M. (2003): Monoclonal antibody therapy for cancer. Annu. Rev. Med., 54, 343-369.
155. Wajant H., Moosmayer D., Wuest T., Bartke T., Gerlach E., Schonherr U., Peters N., Scheurich P. and Pfizenmaier K. (2001): Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene, 20, 4101-4106.
156. Waldmann T. A. (2003): Immunotherapy: past, present and future. Nat. Med., 9, 269-277.
157. Wang X. B., Zhao B. F., Zhao Q., Piao J. H., Liu J., Lin Q. and Huang H. L. (2004): A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently. J. Biochem., 135, 555-565.
158. Watanabe M., Wallace P. K., Keler T., Deo Y. M., Akewanlop C. and Hayes D. F. (1999): Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res. Treat., 53, 199-207.
159. Weiner L. M. and Adams G. P. (2000): New approaches to antibody therapy. Oncogene, 19, 6144-6151.
160. Whelan M., Whelan J., Russell N. and Dalgleish A. (2003): Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today, 8, 253-258.
161. White C. A., Weaver R. L. and Grillo-Lopez A. J. (2001): Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med., 52, 125-145.
162. Xerri L., Bouabdallah R., Devilard E., Hassoun J., Stoppa A. M. and Birg F. (1998): Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br. J. Cancer, 78, 225-232.
163. Xiong H. Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R. A., Deutsch J., Needle M. and Abbruzzese J. L. (2004): Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol., 22, 2610-2616.
164. Yang X. D., Jia X. C., Corvalan J. R., Wang P., Davis C. G. and Jakobovits A. (1999): Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res., 59, 1236-1243.
165. Yonehara S., Ishii A. and Yonehara M. (1989): A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169, 1747-1756.
166. Yovtchev Y. and Nilolov S. (2001): Opportunities for up to date treatment of the colorectal cancer. Radiol. Oncol., 35, 111-115.
167. Zein N., Sinha A. M., McGahren W. J. and Ellestad G. A. (1988): Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198-1201.